格隆汇8月26日丨华显光电(00334.HK)公告，截至2025年6月30日止六個月，集团实现总销量达33.7百万 片，同比增加70.0%，带动总营业额增长至人民币3,170.6百万元，同比增加72.2%。回顾期内，集团通 过持续调整产品结构及优化客户结构，进一步提升盈利能力。在整体业务的大幅增长带动下，集团录得 毛利达人民币118.3百万元，同比增加70.0%，毛利率为3.7%，与去年同期基本持平。集团录得母公司拥 有者利润达人民币51.0百万元，同比增加631.9%。 ...

智通财经APP讯，华显光电(00334)发布截至2025年6月30日止六个月中期业绩，收入31.71亿元(人民 币，下同)，同比增加72.2%;股东应占溢利5104万元，同比增加631.9%;每股基本盈利2.43分。 公告称，回顾期内，集团充分发挥规模化产能及产线布局优势，持续优化业务和产品结构，驱动各类型 产品销量持续攀升，经营业绩显著增长。2025年第二季度，集团销量达到2040万片，季度环比增加 54.4%。回顾期内，集团实现总销量达3370万片，同比增加70.0%，带动总营业额增长。 ...

公告称，回顾期内，集团充分发挥规模化产能及产线布局优势，持续优化业务和产品结构，驱动各类型 产品销量持续攀升，经营业绩显著增长。2025年第二季度，集团销量达到2040万片，季度环比增加 54.4%。回顾期内，集团实现总销量达3370万片，同比增加70.0%，带动总营业额增长。 华显光电(00334)发布截至2025年6月30日止六个月中期业绩，收入31.71亿元(人民币，下同)，同比增加 72.2%;股东应占溢利5104万元，同比增加631.9%;每股基本盈利2.43分。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 China Display Optoelectronics Technology Holdings Limited 華顯光電技術控股有限公 司 （於百慕達註冊成立之有限公司） （股份代號：334） 業績公佈 截至二零二五年六月三十日止六個月 財務摘要 截至六月三十日止六個月未經審核業績 | | 二零二五年 | 二零二四年 | 變動 | | --- | --- | --- | --- | | | （未經審核） | （未經審核） | | | | 人民幣千元 | 人民幣千元 | | | 收入 | 3,170,600 | 1,841,000 | +72.2% | | 毛利 | 118,349 | 69,605 | +70.0% | | 本期間溢利 | 51,040 | 6,974 | +631.9% | | 母公司擁有者應佔溢利 | 51,040 | 6,974 | +631.9% | | 母公司擁有者應佔每股 ...

華顯光電技術控股有限公司（「本公司」）之董事會（「董事會」）謹此宣佈， 將於二零二五年八月二十六日（星期二）舉行董事會會議，以（其中包括）批准 本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績，並於香港 聯合交易所有限公司及本公司之網站上刊登上述業績。 董事會屆時亦會考慮派付截至二零二五年六月三十日止六個月之中期股息（如 有）。 代表董事會 主席 廖騫 香港，二零二五年八月十四日 於本公佈日期，董事會包括主席兼非執行董事廖騫先生；執行董事張鋒先生、習 文波先生、張才力先生及王新福先生；及獨立非執行董事徐慧敏女士、徐岩先生、 李揚先生及陽秋林女士。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Display Optoelectronics Technology Holdings Limited 華顯光電技術控股有限公司 （於百慕達註冊成立之有限公司） (股份代號: 334) 董事會會議通知 ...

Core Viewpoint - Huaxian Optoelectronics (00334) has announced a positive earnings forecast, expecting a significant increase in profits for the first half of 2025, driven by product optimization and strong sales growth [1] Group 1: Earnings Forecast - The company anticipates a profit of no less than RMB 48.8 million for the first half of 2025, representing an increase of at least 600% year-on-year [1] - The profit increase is attributed to a total sales volume increase of at least 60% compared to the same period in 2024 [1] Group 2: Sales Performance - Revenue from all product categories sold during the period is expected to increase by over 70% year-on-year, supported by the integration model with TCL Huaxing Optoelectronics [1] - The first quarter of 2025 saw a 1.8 times year-on-year increase in sales of tablet modules, contributing to an overall revenue growth of 49.7% to RMB 1.394 billion [1] Group 3: Business Model and Market Position - Huaxian Optoelectronics primarily focuses on small to medium-sized LCD modules for smartphones, tablets, and automotive displays, utilizing an ODM model to provide customized solutions for brand manufacturers [1] - The company has established a solid position in the small to medium-sized display module sector, benefiting from vertical integration and customer resources as part of the TCL Technology Group's display industry chain [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Display Optoelectronics Technology Holdings Limited 華顯光電技術控股有限公 司 （於百慕達註冊成立之有限公司） （股份代號：334） 修訂買賣（二零二五至二七年）主協議項下 持續關連交易之收益限額及年度上限 茲提述本公司日期分別為二零二四年九月十日及二零二四年十月十四日之公佈及 通函，內容有關（其中包括）本公司與TCL科技訂立買賣（二零二五至二七年）主協 議。根據買賣（二零二五至二七年）主協議（其中包括），本集團各成員公司可全權 酌情要求自TCL科技集團成員公司採購所需之材料，而TCL科技集團各成員公司 可全權酌情要求自本集團成員公司採購產品。 於二零二五年八月十二日，本公司與TCL科技訂立補充協議，以通過修訂二零 二五年銷售收益限額修訂及補充買賣（二零二五至二七年）主協議。除上述修訂 外，買賣（二零二五至二七年）主協議之所有其他條款及條件 ...

Group 1 - The core point of the article is that Zhejiang Huaxian Optoelectronics Technology Co., Ltd. has obtained a patent for "N-phenylpyrrole derivatives, organic electroluminescent devices, and display or lighting devices" [1] - The patent was granted with the announcement number CN116120345B, and the application date was November 2021 [1] - Zhejiang Huaxian Optoelectronics was established in 2016 and is located in Jiaxing City, primarily engaged in the manufacturing of computers, communications, and other electronic devices [1] Group 2 - The company has a registered capital of 11.48752 million RMB [1] - According to data analysis, Zhejiang Huaxian has invested in three companies and participated in three bidding projects [1] - The company holds 273 patent information entries and has two trademark information entries, along with four administrative licenses [1]

Core Viewpoint - 华显光电 (00334) has announced a positive earnings forecast, expecting a significant increase in profits for the first half of 2025, driven by product optimization and increased sales volume [1] Group 1: Earnings Forecast - The company anticipates a profit attributable to shareholders of no less than RMB 48.8 million for the first half of 2025, representing an increase of at least 600% year-on-year [1] - The profit increase is primarily attributed to the continuous optimization of the product mix [1] Group 2: Sales Performance - Total sales volume is expected to increase by at least 60% compared to the same period in 2024 [1] - Revenue from all product categories sold during the period is projected to increase by over 70% year-on-year, thanks to the recognition from several leading brand clients regarding the panel module integration model with TCL Huaxing Optoelectronics [1]

Group 1 - The Ministry of Transport, Ministry of Finance, and Ministry of Natural Resources have issued a plan to complete the construction and renovation of 300,000 kilometers of rural roads by 2027, aiming to establish a convenient and efficient rural road network [1] - The plan includes implementing 300,000 kilometers of repair and maintenance projects, maintaining a good road condition rate of over 70%, and carrying out safety protection projects on 150,000 kilometers of roads [1] - The initiative aims to enhance rural transportation services and support the vision of a well-structured, high-quality rural transportation system by 2035 [1] Group 2 - U.S. stock markets saw an overall increase, with the Dow Jones rising by 81.38 points (0.19%) and the Nasdaq increasing by 252.87 points (1.21%) [2] - Notable stock movements included Apple rising by 5% due to anticipated investments in U.S. manufacturing, and McDonald's gaining over 3% following better-than-expected earnings [2] - Many popular Chinese concept stocks also saw gains, with Alibaba up over 3% and NIO increasing by over 2% [2] Group 3 - The State Grid reported a record high electricity load for three consecutive days, reaching a maximum load of 1.233 billion kilowatts, an increase of 53 million kilowatts compared to last year's peak [3] - The electricity load is expected to remain above 1.2 billion kilowatts, with a potential decrease anticipated due to upcoming rainfall and cooler temperatures [3] Group 4 - The Hong Kong Monetary Authority intervened in the currency market, buying HKD 8.439 billion after the Hong Kong dollar hit the weak end of its trading band [4] - This action is part of the linked exchange rate system, where the HKMA sells USD and buys HKD to stabilize the currency [4] Group 5 - The China Photovoltaic Industry Association is soliciting opinions on the draft amendment to the Price Law, focusing on price behavior norms and regulatory mechanisms [5] - This initiative aims to reflect the demands of the photovoltaic industry and gather feedback for potential modifications [5] Group 6 - Guangnan Group's subsidiary successfully acquired land use rights in Foshan for RMB 56.16 million, expanding its meat industry chain [6] Group 7 - Caocao Travel is exploring the tokenization of real-world assets and stablecoin payments through a strategic partnership with a licensed financial institution in Hong Kong [7][8] Group 8 - Lianzhong is integrating AI technology into traditional board games, collaborating with tech companies to enhance gaming experiences [9] Group 9 - China National Pharmaceutical Group's self-developed drug TQ05105 has been included in the breakthrough therapy designation program for chronic graft-versus-host disease treatment [10] Group 10 - China Nuclear Technology expects a mid-year profit increase of no less than 15% compared to the previous year [11] Group 11 - Hengrui Medicine's product received orphan drug designation from the FDA, which may provide regulatory advantages in the U.S. market [12] Group 12 - Huaxian Optoelectronics anticipates a significant profit increase of at least 600% for the first half of 2025 [13] Group 13 - New World Development expects a mid-year profit of no less than HKD 800 million, a substantial increase from the previous year's HKD 75.4 million [14] Group 14 - Xinwei Medical expects to achieve a net profit of at least RMB 40 million in the first half of 2025, marking a turnaround from losses [15] Group 15 - Zhiyu Technology anticipates a mid-year profit increase of approximately 108.9% to 126.7% [16] Group 16 - Ningmeng Media expects to achieve a net profit of approximately RMB 10 million to 12 million in the first half of 2025, reversing previous losses [17] Group 17 - Weixin Jinke anticipates a significant profit increase of no less than RMB 200 million for the first half of 2025, reflecting a growth of at least 65% [18] Group 18 - Uni-President China reported a 33.24% increase in shareholder profit to RMB 1.287 billion for the mid-year period [19] Group 19 - BeiGene reported a net profit of USD 94.32 million for the second quarter, marking a turnaround from a loss of USD 120 million in the previous year [20] Group 20 - Maifushi expects to achieve a net profit of approximately RMB 31.8 million to 41 million in the first half of 2025, reversing a significant loss from the previous year [21]